Drugmaker fined $150 million in testosterone booster case

25 July 2017

AbbVie (NYSE: ABBV) has been ordered to pay $150 million to a patient who claimed that the US drugmaker hid the risks of its AndroGel testosterone booster in aggressive advertising campaigns.

Oregon man Jesse Mitchell argued that the company misled him and his doctor about AndroGel's propensity for causing blood clots that can lead to heart attacks. Mr Mitchell suffered a heart attack in 2012, having taken AndroGel for four years.

AbbVie denied the claims, though sales of its testosterone booster have reduced since regulators put more severe label warnings on the product in 2015.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK